Skip to main content

FDA to Address Female Sexual Dysfunction

The federal agency will convene a two-day workshop in October to discuss the development of drugs to treat the issue.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

WIKIMEDIA, SERGIO FABARA MUNOZFemale sexual dysfunction (FSD) may be inching out of the pharmaceutical industry’s shadows as the US Food and Drug Administration (FDA) has announced a two-day, late-October meeting on the issue. The FDA announced on Monday (August 11) that it will convene a workshop on October 27 and 28. The agency has set aside time to hear from FSD patients, researchers, and clinicians who have experience with FSD.

The move comes after critics, such as the Even the Score coalition have complained that the FDA hasn’t approved a single drug to treat FSD, while the agency has approved six types of drugs, sold under 25 different names and formulations, to treat male sexual dysfunction.

Cindy Whitehead, CEO of Sprout Pharmaceuticals—which is currently seeking FDA approval for an FSD drug—told The Wall Street Journal’s Pharmalot that she welcomed the move by the agency. It’s “positive to see that FDA has recognized FSD as one of their 20 priority areas of unmet need under the Patient Focused Drug Development Program,” she wrote in an e-mail. “Based on their outlined goals, this meeting will bring the patient voice forward regarding the impact of living with the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation